Display options
Cite
McCloskey E, Selby P, Davies M, et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res. 2004;19(5):728-36doi: 10.1359/JBMR.040116.
McCloskey, E., Selby, P., Davies, M., Robinson, J., Francis, R. M., Adams, J., Kayan, K., Beneton, M., Jalava, T., Pylkkänen, L., Kenraali, J., Aropuu, S., & Kanis, J. A. (2004). Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 19(5), 728-36. https://doi.org/10.1359/JBMR.040116
McCloskey, Eugene, et al. "Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study." Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research vol. 19,5 (2004): 728-36. doi: https://doi.org/10.1359/JBMR.040116
McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkänen L, Kenraali J, Aropuu S, Kanis JA. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res. 2004 May;19(5):728-36. doi: 10.1359/JBMR.040116. Epub 2004 Jan 19. PMID: 15068495.
Copy Download .nbib Format: NLM
Share it on

J Bone Miner Res. 2004 May;19(5):728-36. doi: 10.1359/JBMR.040116. Epub 2004 Jan 19.

Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Eugene McCloskey, Peter Selby, Mike Davies, John Robinson, Roger M Francis, Judith Adams, Karthik Kayan, Monique Beneton, Tarja Jalava, Liisa Pylkkänen, Juha Kenraali, Sakari Aropuu, John A Kanis

Affiliations

  1. Division of Genomic Medicine, The World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom. [email protected]

PMID: 15068495 DOI: 10.1359/JBMR.040116

Abstract

UNLABELLED: The efficacy of oral clodronate 800 mg daily to reduce vertebral fractures was studied in 593 women with postmenopausal or secondary osteoporosis. The incidence of vertebral fractures was significantly reduced by 46%. The effect was not modified by the underlying cause of osteoporosis or other baseline factors including bone mineral density, QUS, weight, and smoking.

INTRODUCTION: This study aimed to determine if the bisphosphonate, clodronate (Bonefos), reduced the incidence of vertebral fractures in osteoporotic women.

MATERIALS AND METHODS: Women fulfilling the WHO criteria for osteoporosis at the lumbar spine (T-score

RESULTS: Treatment with clodronate was associated with a significant increase in mean spine BMD over 3 years (percent change from baseline, 4.35 +/- 6.34% versus 0.64 +/- 6.02% in the placebo group, p < 0.0001). At the hip, clodronate maintained total BMD, whereas a significant decrease was observed in the placebo group (percent change from baseline 0.70 +/- 5.67% versus -3.03 +/- 6.32% in the placebo group, p < 0.0001). The changes at the spine and hip were similar in both strata. Incident vertebral fractures at 3 years were observed in 63 women in the placebo group and 33 patients receiving clodronate (relative risk, 0.54; 95% CI, 0.37-0.80; p = 0.001). Clodronate significantly reduced vertebral fracture risk in both strata and in women with or without prior vertebral fracture at baseline. Nonvertebral osteoporosis-associated fractures occurred in 21 women in the placebo group and in 14 women treated with clodronate. Treatment was well tolerated, with no significant difference in adverse event rates, including esophagitis, during clodronate treatment.

CONCLUSION: We conclude that clodronate 800 mg daily is a safe and effective treatment to reduce fracture risk in women with osteoporosis, regardless of causation.

Substances

MeSH terms

Publication Types